Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults
Yingying Fang, Xiaoqian Wang, Lu Qi, Yuanxu Tong, Yali Wei, Zhong Li, Chen Liu, Ju Liu, Xiaoqiang Cheng, Xiaoyun Liu, Fang Liu, Yinjuan Li, Yan Li, Long Liu, Mingli Sun, Yu Wang, Xinghe Wang · 2026
Read Safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of STSA-1002, recombinant anti-human C5a fully human monoclonal antibody, in a randomized, first-in-human phase I study in healthy adults by Yingying Fang, Xiaoqian Wang, Lu Qi, Yuanxu Tong, Yali Wei, Zhong Li, Chen Liu, Ju Liu, Xiaoqiang Cheng, Xiaoyun Liu, Fang Liu, Yinjuan Li, Yan Li, Long Liu, Mingli Sun, Yu Wang, Xinghe Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13323816.txt.
Description
Yingying Fang and co-authors run a first-in-human trial of an anti-C5a antibody called STSA-1002, in a 2026 phase I study in healthy adults in China. C5a drives inflammation in virus-linked acute respiratory distress, and the antibody blocks C5a-triggered oxygen radical release in lab tests.
The randomised, double-blind, dose-escalation study gave repeated intravenous doses against placebo. Side effects were frequent in both arms, mostly mild, with a few moderate drug-linked events such as lowered white cell counts and raised liver enzymes. Blood levels rose roughly in step with dose, and free C5a fell below detection after the first dose for weeks. Anti-drug antibodies were also tracked for safety planning.
Catalog record
| CREATOR | Yingying Fang, Xiaoqian Wang, Lu Qi, Yuanxu Tong, Yali Wei, Zhong Li, Chen Liu, Ju Liu, Xiaoqiang Cheng, Xiaoyun Liu, Fang Liu, Yinjuan Li, Yan Li, Long Liu, Mingli Sun, Yu Wang, Xinghe Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47765 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |